Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent levosimendan in progressive heart failure with reduced ejection fraction
ChiCTR2000039232Phase 4Recruiting
- Sponsor
- Fuwai Hospital
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Levosimendan arm with Placebo arm (2 arms). Primary endpoints: Change in 6-minute walk distance and Composite of cardiovascular death and total heart failure rehospitalization. Started Nov 2020; status: recruiting.
02
Drugs
levosimendan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2000039232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039232.